| Metastatic non-small cell lung cancer
Vizimpro vs Tepmetko
Side-by-side clinical, coverage, and cost comparison for metastatic non-small cell lung cancer.Deep comparison between: Vizimpro vs Tepmetko with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTepmetko has a higher rate of injection site reactions vs Vizimpro based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tepmetko but not Vizimpro, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Vizimpro
Tepmetko
At A Glance
Oral
Daily
EGFR inhibitor
Oral
Daily
MET kinase inhibitor
Indications
- Metastatic non-small cell lung cancer
- Metastatic non-small cell lung cancer
Dosing
Metastatic non-small cell lung cancer 45 mg orally once daily until disease progression or unacceptable toxicity; may be taken with or without food.
Metastatic non-small cell lung cancer 450 mg orally once daily with food until disease progression or unacceptable toxicity; dose reduction to 225 mg once daily for adverse reactions, with permanent discontinuation if 225 mg is not tolerated.
Contraindications
—
—
Adverse Reactions
Most common (>20%) Diarrhea, rash, paronychia, stomatitis, decreased appetite, dry skin, decreased weight, alopecia, cough, pruritus
Serious Diarrhea, interstitial lung disease
Most common (>=20%) Edema, nausea, fatigue, musculoskeletal pain, diarrhea, dyspnea, decreased appetite, rash
Serious Pleural effusion, pneumonia, edema, general health deterioration, dyspnea, musculoskeletal pain, pulmonary embolism
Pharmacology
Dacomitinib is an irreversible inhibitor of the kinase activity of the human EGFR family (EGFR/HER1, HER2, and HER4) and certain EGFR activating mutations (exon 19 deletion or exon 21 L858R substitution mutation), demonstrating dose-dependent inhibition of EGFR and HER2 autophosphorylation and tumor growth in preclinical models.
Tepotinib is a kinase inhibitor that targets MET, including variants with exon 14 skipping alterations, inhibiting HGF-dependent and -independent MET phosphorylation and MET-dependent downstream signaling pathways.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Vizimpro
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Tepmetko
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
UnitedHealthcare
Vizimpro
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (1/8)
Tepmetko
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Vizimpro
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Tepmetko
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Non-Small Cell Lung Cancer (NSCLC)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Non-Small Cell Lung Cancer (NSCLC)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
VizimproView full Vizimpro profile
TepmetkoView full Tepmetko profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.